Business Context and Reporting Period
This Form 8-K Current Report is filed by Crinetics Pharmaceuticals, Inc. on April 10, 2026. The report addresses the departure of a senior officer and the subsequent appointment of that individual as an independent consultant.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on executive compensation and personnel changes rather than financial performance.
Material Changes
- Executive Departure: Jeff Knight resigned as Chief Development and Operating Officer, effective April 10, 2026.
- Consulting Appointment: Mr. Knight was immediately appointed as an Independent Consultant under a new agreement effective April 10, 2026.
- Compensation Structure: Mr. Knight will be compensated at $400 per hour for up to 20 hours per month, plus reimbursement for pre-approved travel and out-of-pocket expenses.
- Equity Treatment: Unvested restricted stock units and stock options were forfeited on the resignation date. Vested stock options remain exercisable until three months following the end of the consulting period (or earlier if terminated for cause).
Outlook, Risks, and Unusual Items
Consulting Agreement Terms: The agreement covers a one-year term ending April 10, 2027, with an option to renew for an additional six months if mutually agreed upon in writing. The agreement includes a general release of all claims by Mr. Knight against the Company and extends certain indemnification rights to him during the consulting period.
Risks: The filing does not explicitly detail new operational risks, though the transition of leadership in development and operations may present execution risks not quantified in this document.
Investor Verification Checklist
- Verify the specific scope of "operational and clinical development matters" Mr. Knight will handle as a consultant.
- Confirm the exact number of vested stock options remaining exercisable for Mr. Knight.
- Review the full text of the Independent Consultant Agreement (Exhibit 10.1) for termination clauses and non-compete provisions.
- Monitor subsequent filings for the appointment of a permanent replacement for the Chief Development and Operating Officer role.